Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)
Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –
Innoviva cash
Cash and short-term investments held at the end of each period.
Innoviva's cash was $581.39M at Sep 30, 2026. For fiscal 2025 it was $550.94M, up 80.7% from the year before. Over ten years it grew 11.4% a year on average. The highest annual figure on record is $550.94M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $550.94M | +80.7% |
| FY2024 | Dec 31, 2024 | $304.96M | +57.6% |
| FY2023 | Dec 31, 2023 | $193.51M | -33.5% |
| FY2022 | Dec 31, 2022 | $291.05M | +44.4% |
| FY2021 | Dec 31, 2021 | $201.53M | -18.2% |
| FY2020 | Dec 31, 2020 | $246.49M | -29.7% |
| FY2019 | Dec 31, 2019 | $350.85M | +205.3% |
| FY2018 | Dec 31, 2018 | $114.91M | -11.0% |
| FY2017 | Dec 31, 2017 | $129.08M | -14.2% |
| FY2016 | Dec 31, 2016 | $150.43M | -19.7% |
| FY2015 | Dec 31, 2015 | $187.28M | -22.1% |
| FY2014 | Dec 31, 2014 | $240.50M | -48.3% |
| FY2013 | Dec 31, 2013 | $465.13M | +87.2% |
| FY2012 | Dec 31, 2012 | $248.49M | +3.1% |
| FY2011 | Dec 31, 2011 | $240.92M | -22.2% |
| FY2010 | Dec 31, 2010 | $309.63M | +551.3% |
| FY2009 | Dec 31, 2009 | $47.54M | -48.5% |
| FY2008 | Dec 31, 2008 | $92.28M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $581.39M | +22.0% |
| Q2 FY2026 | Jun 30, 2026 | $570.39M | +43.5% |
| Q1 FY2026 | Mar 31, 2026 | $603.09M | +89.0% |
| Q4 FY2025 | Dec 31, 2025 | $550.94M | +80.7% |
| Q3 FY2025 | Sep 30, 2025 | $476.51M | +82.8% |
| Q2 FY2025 | Jun 30, 2025 | $397.53M | +83.2% |
| Q1 FY2025 | Mar 31, 2025 | $319.09M | +78.9% |
| Q4 FY2024 | Dec 31, 2024 | $304.96M | +57.6% |
| Q3 FY2024 | Sep 30, 2024 | $260.63M | +44.8% |
| Q2 FY2024 | Jun 30, 2024 | $217.00M | +25.4% |
| Q1 FY2024 | Mar 31, 2024 | $178.36M | +23.8% |
| Q4 FY2023 | Dec 31, 2023 | $193.51M | -33.5% |
| Q3 FY2023 | Sep 30, 2023 | $180.00M | -40.2% |
| Q2 FY2023 | Jun 30, 2023 | $173.03M | -39.0% |
| Q1 FY2023 | Mar 31, 2023 | $144.05M | -33.6% |
| Q4 FY2022 | Dec 31, 2022 | $291.05M | +44.4% |
| Q3 FY2022 | Sep 30, 2022 | $301.07M | +122.8% |
| Q2 FY2022 | Jun 30, 2022 | $283.58M | +555.4% |
| Q1 FY2022 | Mar 31, 2022 | $216.80M | -23.4% |
| Q4 FY2021 | Dec 31, 2021 | $201.53M | -18.2% |
| Q3 FY2021 | Sep 30, 2021 | $135.12M | -71.8% |
| Q2 FY2021 | Jun 30, 2021 | $43.27M | -89.6% |
| Q1 FY2021 | Mar 31, 2021 | $282.89M | -26.3% |
| Q4 FY2020 | Dec 31, 2020 | $246.49M | -29.7% |
| Q3 FY2020 | Sep 30, 2020 | $479.19M | +61.2% |
| Q2 FY2020 | Jun 30, 2020 | $417.15M | +67.1% |
| Q1 FY2020 | Mar 31, 2020 | $383.95M | +99.8% |
| Q4 FY2019 | Dec 31, 2019 | $350.85M | +205.3% |
| Q3 FY2019 | Sep 30, 2019 | $297.20M | +435.7% |
| Q2 FY2019 | Jun 30, 2019 | $249.66M | +132.2% |
| Q1 FY2019 | Mar 31, 2019 | $192.18M | +240.4% |
| Q4 FY2018 | Dec 31, 2018 | $114.91M | -11.0% |
| Q3 FY2018 | Sep 30, 2018 | $55.48M | -67.0% |
| Q2 FY2018 | Jun 30, 2018 | $107.54M | -20.7% |
| Q1 FY2018 | Mar 31, 2018 | $56.46M | -66.8% |
| Q4 FY2017 | Dec 31, 2017 | $129.08M | -14.2% |
| Q3 FY2017 | Sep 30, 2017 | $168.19M | – |
| Q2 FY2017 | Jun 30, 2017 | $135.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $169.81M | – |
| Q4 FY2016 | Dec 31, 2016 | $150.43M | – |
See a number that looks wrong?